Icotrokinra Sustains Psoriasis Skin Clearance Through 2 Years
Two-year ICONIC-LEAD data show oral IL-23 receptor antagonist icotrokinra sustained skin clearance in plaque psoriasis, strengthening its case against injectable biologics.
Topic
Icotrokinra
Topic
Icotrokinra
Icotrokinra Sustains High-Impact Psoriasis Site Clearance Through 2 Years
Phase 3 ICONIC-TOTAL data show oral icotrokinra achieved IGA 0/1 in 70% of psoriasis patients at Week 112, with 89% genital clear…
Icotrokinra Holds Skin Clearance at High-Impact Psoriasis Sites at 2 Years
Icotrokinra sustained skin clearance at high-impact psoriasis sites through 2 years, per Dermatology Times. The milestone extends…
Icotrokinra Sustains High-Impact Site Clearance at 2 Years
Two-year ICONIC-TOTAL extension data show icotrokinra sustains clearance of high-impact psoriasis sites — scalp, face, palms, sol…
J&J Reports Two-Year Icotrokinra Durability Data in Plaque Psoriasis
J&J reports two-year icotrokinra durability data in difficult-to-treat plaque psoriasis, positioning the oral agent as a first-li…
FDA Approves Icotrokinra, First Oral Targeted Peptide for Plaque Psoriasis
The FDA has approved icotrokinra, the first oral targeted peptide for plaque psoriasis, adding a new formulation category to the…
FDA Approves Icotrokinra, First Targeted Oral Peptide for Plaque Psoriasis
FDA approves icotrokinra, the first targeted oral peptide for moderate-to-severe plaque psoriasis, expanding systemic options bey…
FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis
The FDA has approved icotrokinra, the first oral IL-23 receptor antagonist for psoriasis, giving dermatologists a tablet-based op…
FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis
FDA approval of icotrokinra delivers the first oral IL-23 inhibitor for plaque psoriasis, shifting a proven biologic pathway from…